DexCom (DXCM) Stock Buyback History
TTM buyback yield 1.95% · Shareholder yield (TTM) 1.95%.
DexCom
DXCM
TTM buyback yield
1.95%
Shareholder yield (TTM)
1.95%
5Y share count change
4.0%
TTM buyback spend
$500.00M
SBC coverage (TTM)
3.13x
Diluted vs basic shares (annual)
Weighted average shares from the income statement: diluted (EPS denominator and typical buyback-yield basis) compared with basic.
Shares outstanding (annual)
Year-over-year change in diluted weighted average shares (industry-standard for EPS and per-share capital return). Green is fewer shares vs the prior fiscal year; red is growth (dilution). The earliest year shown has no prior year to compare.
Dividend & buyback yield
Buybacks vs stock-based compensation
TTM coverage: 3.13x (buybacks ÷ SBC). Bars are fiscal-year totals.
Buyback spending history
| Year | Buybacks | SBC | Net | Shares (dil.) | YoY shares | Buyback yield |
|---|---|---|---|---|---|---|
| 2025 | $500.00M | $159.60M | $340.40M | 0.41B | -1.7% | 1.95% |
| 2024 | $750.00M | $170.40M | $579.60M | 0.41B | -3.0% | 2.42% |
| 2023 | $688.70M | $150.80M | $537.90M | 0.43B | -0.5% | 1.44% |
| 2022 | $557.70M | $126.50M | $431.20M | 0.43B | -0.3% | 1.27% |
| 2021 | $0.00 | $113.40M | −$113.40M | 0.43B | 9.9% | — |
| 2020 | $0.00 | $119.40M | −$119.40M | 0.39B | 5.6% | — |
| 2019 | $0.00 | $102.70M | −$102.70M | 0.37B | 4.6% | — |
| 2018 | $100.00M | $101.90M | −$1.90M | 0.35B | 2.2% | 0.94% |
| 2017 | $0.00 | $106.20M | −$106.20M | 0.35B | 3.2% | — |
| 2016 | $0.00 | $110.80M | −$110.80M | 0.33B | 4.8% | — |
| 2015 | $0.00 | $82.70M | −$82.70M | 0.32B | 6.1% | — |
| 2014 | $0.00 | $50.00M | −$50.00M | 0.30B | 5.8% | — |
| 2013 | $0.00 | $24.60M | −$24.60M | 0.28B | 3.5% | — |
| 2012 | $0.00 | $18.40M | −$18.40M | 0.27B | 4.7% | — |
| 2011 | $0.00 | $13.51M | −$13.51M | 0.26B | 15.3% | — |
| 2010 | $0.00 | $9.44M | −$9.44M | 0.23B | 28.3% | — |
| 2009 | $0.00 | $8.37M | −$8.37M | 0.18B | 50.4% | — |
| 2008 | $0.00 | $7.68M | −$7.68M | 0.12B | 4.1% | — |
| 2007 | $2.73M | $6.12M | −$3.39M | 0.11B | 4.0% | 1.09% |
| 2006 | $0.00 | $5.85B | −$5.85B | 0.11B | 43.8% | — |
| 2005 | $0.00 | $1.67B | −$1.67B | 0.08B | 728.7% | — |
| 2004 | $0.00 | $0.00 | $0.00 | 0.01B | 5.3% | — |
| 2003 | $0.00 | $0.00 | $0.00 | 0.01B | — | — |
Buybacks vs dividends (share of cash returned)
Buyback capacity (TTM)
TTM buybacks vs headroom (FCF − dividends, TTM)46% of headroom
Headroom $1.08B (TTM FCF − TTM dividends, clamped at zero).
Frequently asked questions
Does DexCom buy back its own stock?
- Yes, DexCom (DXCM) has repurchased shares in recent periods. See the history table and charts on this page for amounts and trends.
How much does DexCom spend on share buybacks?
- Trailing twelve months (TTM) buyback spend is about $500.00M (sum of the last four quarterly cash-flow periods in our data). Figures are illustrative; verify in filings.
What is DexCom's buyback yield?
- TTM buyback yield is about 1.95% (TTM buyback spend divided by market cap at the latest quarter-end in our data).
What is DexCom's shareholder yield?
- Shareholder yield combines dividend yield and buyback yield. For the latest period we show approximately 1.95% combined (TTM-based where available).
Is DexCom diluting shareholders?
- Compare stock-based compensation (SBC) to buybacks in the chart above. Net effect varies by year; see annual buyback vs SBC bars and the history table.
How has DexCom's share count changed?
- Diluted weighted average shares changed by about 4.0% over roughly five fiscal years (annual income statement data).